Signatur Biosciences

About Signatur Biosciences

Signatur Biosciences develops smart PCR kits that utilize their PCRchitectur technology to detect gene expression signatures for complex diseases using standard qPCR machines. This approach eliminates the need for multiple tests and expensive equipment, streamlining the diagnostic process and making precision medicine more accessible.

```xml <problem> Traditional PCR diagnostics for complex diseases require either running numerous tests in parallel or upgrading to expensive, complicated machinery like sequencers. Complex preparation and analysis workflows, along with high-tech machines, increase the time and cost of diagnosis, creating a bottleneck for precision medicine adoption. </problem> <solution> Signatur Biosciences develops smart PCR kits that utilize their PCRchitectur technology to detect gene expression signatures for complex diseases using standard qPCR machines. This approach eliminates the need for multiple tests and expensive equipment, streamlining the diagnostic process and making precision medicine more accessible. The kits seamlessly integrate into existing clinical workflows and ubiquitous laboratory instruments. The PCRchitectur technology condenses the detection and interpretation of a panel of RNA biomarkers into a single test. </solution> <features> - Smart PCR kits designed to detect gene expression signatures. - PCRchitectur technology enables the use of standard qPCR machines for complex disease diagnosis. - Streamlined workflow integrates seamlessly into existing clinical laboratory processes. - Eliminates the need for multiple PCR tests or expensive sequencing equipment. - Condenses the detection and interpretation of multiple RNA biomarkers into a single test. </features> <target_audience> The primary target audience includes clinical laboratories and healthcare providers seeking to improve the accessibility and efficiency of precision diagnostics for complex diseases. </target_audience> ```

What does Signatur Biosciences do?

Signatur Biosciences develops smart PCR kits that utilize their PCRchitectur technology to detect gene expression signatures for complex diseases using standard qPCR machines. This approach eliminates the need for multiple tests and expensive equipment, streamlining the diagnostic process and making precision medicine more accessible.

Where is Signatur Biosciences located?

Signatur Biosciences is based in East New York, United States.

When was Signatur Biosciences founded?

Signatur Biosciences was founded in 2022.

How much funding has Signatur Biosciences raised?

Signatur Biosciences has raised 500000.

Who founded Signatur Biosciences?

Signatur Biosciences was founded by Celestin de Wergifosse.

  • Celestin de Wergifosse - Co-founder/CEO
Location
East New York, United States
Founded
2022
Funding
500000
Employees
10 employees
Major Investors
Y Combinator
Looking for specific startups?
Try our free semantic startup search

Signatur Biosciences

Score: 100/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

Signatur Biosciences develops smart PCR kits that utilize their PCRchitectur technology to detect gene expression signatures for complex diseases using standard qPCR machines. This approach eliminates the need for multiple tests and expensive equipment, streamlining the diagnostic process and making precision medicine more accessible.

signatur.bio700+
cb
Crunchbase
Founded 2022 – East New York, United States

Funding

$

Estimated Funding

$500K+

Major Investors

Y Combinator

Team (10+)

Celestin de Wergifosse

Co-founder/CEO

John Goertz

I teach machine learning to molecules while building Signatur Biosciences.

Company Description

Problem

Traditional PCR diagnostics for complex diseases require either running numerous tests in parallel or upgrading to expensive, complicated machinery like sequencers. Complex preparation and analysis workflows, along with high-tech machines, increase the time and cost of diagnosis, creating a bottleneck for precision medicine adoption.

Solution

Signatur Biosciences develops smart PCR kits that utilize their PCRchitectur technology to detect gene expression signatures for complex diseases using standard qPCR machines. This approach eliminates the need for multiple tests and expensive equipment, streamlining the diagnostic process and making precision medicine more accessible. The kits seamlessly integrate into existing clinical workflows and ubiquitous laboratory instruments. The PCRchitectur technology condenses the detection and interpretation of a panel of RNA biomarkers into a single test.

Features

Smart PCR kits designed to detect gene expression signatures.

PCRchitectur technology enables the use of standard qPCR machines for complex disease diagnosis.

Streamlined workflow integrates seamlessly into existing clinical laboratory processes.

Eliminates the need for multiple PCR tests or expensive sequencing equipment.

Condenses the detection and interpretation of multiple RNA biomarkers into a single test.

Target Audience

The primary target audience includes clinical laboratories and healthcare providers seeking to improve the accessibility and efficiency of precision diagnostics for complex diseases.